Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a challenging sojourn that has taken us away, albeit briefly, from the Pharmalot campus. We are, in fact, enjoying getting out and about again. Meanwhile, this marks the middle of the week, which means we have also managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few tidbits to help you on your own journey. Have a grand day, and drop us a line if you hear something saucy. …

Moderna (MRNA) and the National Institutes of Health are in a bitter dispute over who deserves credit for inventing the central component of the company’s Covid-19 vaccine, a conflict that has broad implications for the vaccine’s long-term distribution and billions of dollars in future profits, The New York Times writes. The vaccine grew out of a four-year collaboration between Moderna and the NIH, and the agency says three scientists at its Vaccine Research Center worked with Moderna scientists to design the genetic sequence that prompts the vaccine to produce an immune response, and should be named on the “principal patent application.” Moderna disagrees.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment